Suggested Remit: To appraise the clinical and cost effectiveness of avapritinib within its marketing authorisation for unresectable or metastatic gastrointestinal stromal tumours (GIST).
 
Status In progress
Process STA 2018
ID number 1626

Provisional Schedule

Expected publication 16 December 2020

Project Team

Project lead Gavin Kenny

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Consultees

Companies sponsors Blueprint Medicines (avapritinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups GIST Support UK
  Sarcoma UK
Professional groups Association of Cancer Physicians
  British Society of Gastroenterology
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (imatinib) (confidentiality agreement not signed, not participating)
  Aurobindo Pharma (imatinib) (confidentiality agreement not signed, not participating)
  Bayer (regorafenib)
  Cipla EU (imatinib) (confidentiality agreement not signed, not participating)
  Dr. Reddy's Laboratories (imatinib) (confidentiality agreement not signed, not participating)
  Intrapharma (imatinib) (confidentiality agreement not signed, not participating)
  Mylan (imatinib) (confidentiality agreement not signed, not participating)
  Novartis (imatinib) (confidentiality agreement not signed, not participating)
  Pfizer (sunitinib) (confidentiality agreement not signed, not participating)
  Rivopharm (imatinib) (confidentiality agreement not signed, not participating)
  Sandoz (imatinib) (confidentiality agreement not signed, not participating)
  Teva (imatinib) (confidentiality agreement not signed, not participating)
  Wockhardt (imatinib) (confidentiality agreement not signed, not participating)
  Zentiva (imatinib) (confidentiality agreement not signed, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
19 February 2020 Invitation to participate
09 September 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-February 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
31 July 2019 - 29 August 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 April 2019 In progress. DHSC Referral Received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance